PTC Therapeutics Acquires ST-920 Fabry Disease Program
PTC Therapeutics is acquiring the BLA-stage ST-920 Fabry disease program for $111M upfront and up to $100M in contingent milestone payments
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.